PellePharm's Series B Round

PellePharm raised a round of funding on July 24, 2015.

PellePharm is developing topical patidegib, a first-in-class topical hedgehog inhibitor, to decrease the number of surgically-eligible basal cell carcinomas in Gorlin Syndrome patients.…

Articles about PellePharm's Series B Round: